Ginkgo Bioworks Holdings (DNA) EBITDA Margin (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) reported EBITDA Margin of 427.46% for Q1 2026, down 19204.0% on a YoY basis from N/an in Q1 2025, and down 76.47% quarter-over-quarter from 242.23% in Q4 2025.
Ginkgo Bioworks Holdings (DNA) EBITDA Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings has reported EBITDA Margin for 7 years, with the latest figure at 427.46% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 19204.0% year-over-year to 427.46%; the trailing twelve-month figure through Mar 2026 stood at 213.96% (down 661.0% YoY), and the FY2025 full-year result was 181.66%, up 6072.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 427.46%, down from 242.23% in the prior quarter.
- The five-year high for EBITDA Margin was 61.11% in Q3 2024, with the low at 1012.9% in Q3 2022.
- Historically, EBITDA Margin has averaged 353.97% across 5 years, with a median of 252.72% in 2023.
- The largest YoY upside for EBITDA Margin was 96382 bps in 2022 against a maximum downside of 97853 bps in 2022.
- Ginkgo Bioworks Holdings' EBITDA Margin stood at 170.73% in 2022, then slumped by 249 bps to 596.49% in 2023, then surged by 58 bps to 249.97% in 2024, then gained by 3 bps to 242.23% in 2025, then sank by 76 bps to 427.46% in 2026.
- The last three EBITDA Margin figures came in at 427.46% (Q1 2026), 242.23% (Q4 2025), and 207.05% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | 546.79 Mn | 546.79 Mn | 16.38 Mn | -427.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -427.46% |
| Dec 31, 2025 | -242.23% |
| Sep 30, 2025 | -207.05% |
| Jun 30, 2025 | -116.52% |
| Mar 31, 2025 | -235.42% |
| Dec 31, 2024 | -249.97% |
| Sep 30, 2024 | -61.11% |
| Jun 30, 2024 | -386.71% |
| Mar 31, 2024 | -445.25% |
| Dec 31, 2023 | -596.49% |
| Sep 30, 2023 | -549.32% |
| Jun 30, 2023 | -214.73% |
| Mar 31, 2023 | -252.72% |
| Dec 31, 2022 | -170.73% |
| Sep 30, 2022 | -1,012.90% |
| Jun 30, 2022 | -447.92% |
| Mar 31, 2022 | -401.04% |
| Dec 31, 2021 | -1,134.55% |
| Sep 30, 2021 | -34.37% |
| Jun 30, 2021 | -137.38% |